Sonnet BioTherapeutics Statistics Share Statistics Sonnet BioTherapeutics has 6.26M
shares outstanding. The number of shares has increased by 386.81%
in one year.
Shares Outstanding 6.26M Shares Change (YoY) 386.81% Shares Change (QoQ) 3.27% Owned by Institutions (%) 0.05% Shares Floating 5.71M Failed to Deliver (FTD) Shares 38,508 FTD / Avg. Volume 0.99%
Short Selling Information The latest short interest is 1.14M, so 34.35% of the outstanding
shares have been sold short.
Short Interest 1.14M Short % of Shares Out 34.35% Short % of Float 34.63% Short Ratio (days to cover) 1
Valuation Ratios The PE ratio is -0.59 and the forward
PE ratio is -0.03.
Sonnet BioTherapeutics's PEG ratio is
0.01.
PE Ratio -0.59 Forward PE -0.03 PS Ratio 235.35 Forward PS 3200.4 PB Ratio -9.02 P/FCF Ratio -0.51 PEG Ratio 0.01
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Sonnet BioTherapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 0.66,
with a Debt / Equity ratio of -0.27.
Current Ratio 0.66 Quick Ratio 0.66 Debt / Equity -0.27 Debt / EBITDA -0.01 Debt / FCF -0.02 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $1.43K Profits Per Employee $-572.09K Employee Count 13 Asset Turnover 0.01 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -48.14% in the
last 52 weeks. The beta is 1.05, so Sonnet BioTherapeutics's
price volatility has been higher than the market average.
Beta 1.05 52-Week Price Change -48.14% 50-Day Moving Average 3.11 200-Day Moving Average 2.25 Relative Strength Index (RSI) 45.36 Average Volume (20 Days) 3,909,041
Income Statement In the last 12 months, Sonnet BioTherapeutics had revenue of 18.63K
and earned -7.44M
in profits. Earnings per share was -11.35.
Revenue 18.63K Gross Profit 18.63K Operating Income -11.85M Net Income -7.44M EBITDA -11.77M EBIT -11.85M Earnings Per Share (EPS) -11.35
Full Income Statement Balance Sheet The company has 149.46K in cash and 130.86K in
debt, giving a net cash position of 18.59K.
Cash & Cash Equivalents 149.46K Total Debt 130.86K Net Cash 18.59K Retained Earnings -117.68M Total Assets 3.84M Working Capital 83.99K
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -8.61M
and capital expenditures 0, giving a free cash flow of -8.61M.
Operating Cash Flow -8.61M Capital Expenditures n/a Free Cash Flow -8.61M FCF Per Share -13.14
Full Cash Flow Statement Margins Gross margin is 100%, with operating and profit margins of -63617.91% and -39929.3%.
Gross Margin 100% Operating Margin -63617.91% Pretax Margin -39929.3% Profit Margin -39929.3% EBITDA Margin -63171.67% EBIT Margin -63617.91% FCF Margin -46213.48%
Dividends & Yields SONN does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for SONN is $20,
which is 551.5% higher than the current price. The consensus rating is "Buy".
Price Target $20 Price Target Difference 551.5% Analyst Consensus Buy Analyst Count 1
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Sep 30, 2024. It was a
backward
split with a ratio of 1:8.
Last Split Date Sep 30, 2024 Split Type backward Split Ratio 1:8
Scores Altman Z-Score -53.13 Piotroski F-Score 2
